LeonaBio (NASDAQ: LONA) has appointed Mark F. Kubic as chief business officer (CBO) to lead the company’s business development strategy and execution.
Mr. Kubik served as a strategic consultant to LeonaBio and played a key role in its December 2025 transformational transaction to acquire rights to the Phase 3 lasofoxifene program for metastatic breast cancer.
In a statement, Mark Litton, PhD, president and CEO of LeonaBio, commented, “Mark’s appointment comes at a pivotal moment for LeonaBio. His deep operational experience, global network, and proven ability to execute transformative transactions will be essential as we advance lasofoxifene in Phase 3 development in metastatic breast cancer and continue building a diversified pipeline in oncology and neurodegeneration. Over his 25-year career, Mark has repeatedly demonstrated a rare combination of strategic vision, transaction leadership, and scientific fluency that enables organizations to unlock meaningful value. We are thrilled to welcome him to the executive team and look forward to his leadership in shaping LeonaBio’s next phase of growth.”
